The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
Central Garden & Pet Company
CENT · Nasdaq · USD · Market cap $387M · 6,000 employees
Central Garden & Pet Company produces and distributes various products for the lawn and garden, and pet supplies markets in the United States.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price47.07 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $41.40 to $65.81, base estimate $52.82 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Central Garden & Pet Company holds its Markup at $47.07. The statistical read favours the sellers, held for 222 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 222 days |
| Price at the screen | $47.07 |
| Valuation | 14.85 trailing · 13.12 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.54 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 39.73% | Below 33% | Interest-bearing debt is 39.7% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 33.31% | Below 49% | Money owed to the company is 33.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.80% | Below 5% | Only 0.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Central Garden & Pet's business is in a permissible area, but its interest-bearing debt is about 40% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CENT's ethical verdict changes
Today CENT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly an 11% discount to our $52.82 fair value.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 10.9% discount to the base estimate.
Third-party analyst targets: 2 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $52.82, with a range of $41.40 to $65.81, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPet treats and lawn feed rarely spark investor excitement
When a dog owner reaches for chews or a gardener stocks up on fertiliser, Central Garden & Pet sits behind the transaction. The business splits between pet supplies and garden products, both steady categories that grow with household spending rather than economic booms. Revenue is rising 9 percent, the forward multiple sits at 14.2 times, and the shares trade 11 percent below our fair value of 48.41 dollars. Yet the opportunity rating remains none, because the 5 percent profit margin and 11 percent return on equity show limited ability to compound capital.
The ethical screen clears without issue, and two analysts carry a buy consensus with a 48 dollar median target. That leaves a narrow gap between price and value, but nothing that suggests durable advantage or accelerating growth. Unknown moat and thin returns on equity keep the story ordinary rather than compelling.
Cyclical garden demand can swing with weather and housing cycles, while pet margins stay under pressure from private-label competition. Low returns signal the risk of value traps where earnings look stable yet fail to lift the share price over time. Analysis, not advice.
| Forward P/E | 13.1xreasonably valued |
| Trailing P/E | 14.9xreasonably valued |
| EPS, trailing | 2.70 |
| EPS, forward | 3.06 |
| Revenue growth | -8.2%revenue is shrinking |
| Profit margin | 5.4%thin but positive margins |
| Return on equity | 10.0%a modest return on shareholder capital |
| FCF yield | 13.65% |
| Debt to equity | 0.81moderate, manageable leverage |
| Current ratio | 3.79comfortably covers its short-term bills |
| Beta | 0.54steadier than the market |
| Short interest, float | 0.08% |
| 52-week range | 28.77 - 46.97 |
| Market cap | $387M |
| Employees | 6,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCENT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (2 analysts) rates it none, with a mean price target of $48.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Are Consumer Discretionary Stocks Lagging Central Garden & Pet (CENTA) This Year? Zacks · 16 Sep 2026
- 3 Russell 2000 Stocks That Fall Short StockStory · 9 Sep 2026
- Should Value Investors Buy Central Garden & Pet (CENTA) Stock? Zacks · 9 Sep 2026
- Central Garden & Pet (CENT) Lifts Profit Outlook As Valuation Debate Sharpens Simply Wall St. · 5 Sep 2026
- Central Garden (CENT) Down 10.4% Since Last Earnings Report: Can It Rebound? Zacks · 4 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-21 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-21 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-21 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-13 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-07 | Ro Khanna | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $37.76 | +11.3% | · | $1,113 | +11.3% |
| 2 months | $37.38 | +12.4% | · | $1,124 | +12.4% |
| 3 months | $36.49 | +15.2% | · | $1,152 | +15.2% |
| 6 months | $33.76 | +24.5% | · | $1,245 | +24.5% |
| 1 year | $36.33 | +15.7% | · | $1,157 | +15.7% |
| 2 years | $40.69 | +3.3% | · | $1,033 | +3.3% |
| 3 years | $29.77 | +41.2% | · | $1,412 | +41.2% |
| 5 years | $43.78 | -4.0% | · | $960 | -4.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CENT does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.